Minimal three-arm oral regimen for healthspan: mechanistic alignment with parental-lifespan GWAS transcriptomic signals
A large genome-wide association study of parental lifespan was reported in 2019. A later transcriptome-wide association study (TWAS) identified transcriptional programs associated with longer genetically predicted surviv
This short communication proposes a minimal three-arm oral regimen designed to align with mechanistic signals derived from large-scale genetic studies of parental lifespan. The approach targets specific nodes within the pruning-plasticity-metabolic triad, aiming to extend healthspan through interventions that mirror transcriptional programs associated with longer genetically predicted survival. In a laboratory or metabolic research context, such strategies offer a framework for evaluating how systemic interventions might influence aging trajectories without relying on invasive procedures.
The proposed regimen consists of three distinct components: the Cheung Glutamatergic Regimen, daily nicotinamide mononucleotide and N-acetylcysteine with pulsed senolytics, and GLP-1 receptor agonism. Each arm targets a separate node within the pruning-plasticity-metabolic triad. The NAD+/senescence arm serves as the primary mechanistic anchor, while GLP-1 receptor agonism provides secondary metabolic support, and the glutamatergic arm remains exploratory.
The authors note that the foundational transcriptome-wide association study (TWAS) remains a preprint, and direct combination data are lacking. However, the components show plausible but uneven mechanistic alignment with the TWAS signals. The Cheung Glutamatergic Regimen includes low-dose dextromethorphan potentiated by a CYP2D6 inhibitor together with piracetam and L-glutamine as an exploratory adjunct aimed at preserving residual functional connectivity.
The regimen is fully oral, uses conservative dosing, and draws on prior therapeutic or human-exposure data. However, the proposed combination has no established safety profile. While individual components have been studied in isolation, their combined effects remain unverified. This limitation underscores the need for further investigation before clinical application.
In summary, this communication outlines a research-oriented strategy that integrates findings from genetic and transcriptomic studies into a practical intervention framework. The authors emphasize that while the mechanistic alignment is plausible, the regimen requires carefully designed, safety-focused pilot evaluation to confirm efficacy and tolerability in controlled settings.